EirGenix和Sandoz就HER2的生物类似EG1206A(不包括亚洲部分地区)达成了一项全球交易,支付和分享利润最高达152M美元。 EirGenix and Sandoz struck a global deal for HER2 biosimilar EG1206A, excluding parts of Asia, with up to $152M in payments and shared profits.

2025年11月12日, EirGenix 宣布与Sandoz达成全球独家许可协议, EirGenix announced on November 12, 2025, a global exclusive licensing deal with Sandoz for its HER2 biosimilar EG1206A, a version of Roche’s Perjeta®, excluding several Asian markets. 该协议包括至多1.52亿美元的付款和未来利润分享。 The agreement includes up to $152 million in payments and future profit-sharing. EirGenix将管理开发和制造业,Sandoz则负责商业化。 EirGenix will manage development and manufacturing, while Sandoz handles commercialization. 1206AEG1206A已完成了关键研究,并收到了支持简化发展道路的监管反馈。 EG1206A has completed key studies and received regulatory feedback supporting an abbreviated development path. 紧接着EirGenix先前与Sandoz合作, 研究一种与Tstruzumab相似的生物形态。 This follows EirGenix’s prior collaboration with Sandoz on a trastuzumab biosimilar. HER2-呈阳性的乳腺癌影响到全球约20%的病例,而且随着需求的增长,生物相似性可扩大治疗机会。 HER2-positive breast cancer affects about 20% of global cases, and the biosimilar could expand treatment access as demand grows.